RxDoctor Payments Data

Ira Goodman, MD

Interventional Pain Management · Burr Ridge, ILNPI 1710984794

Payments from drug & device makers

$2,253in general payments, 2019–2025

Across 73 payments — averaging $30.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$869
  • Biotronik NRO, Inc.$273
  • Boston Scientific$256
  • Flowonix Medical Incorporated$230
  • Collegium Pharmaceutical, Inc.$212
  • Vertiflex, Inc.$157
  • plus $256 from 8 others

What the payments were for

  • Food & beverage$1,92485%
  • Education$994%
  • Entertainment$23010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain management providers in Illinoisto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$209,903
Medicare patients
152
Services billed
1,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl35$32,978
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen311$13,181
Morphine Sulfate ErMorphine Sulfate204$7,017
Fentanyl71$6,918
Xtampza ErOxycodone Myristate11$6,213
Oxymorphone Hcl ErOxymorphone Hcl12$6,059
SavellaMilnacipran Hcl12$5,906
Oxycodone Hcl185$5,790
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen117$5,499
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$3,586
Hydromorphone Hcl92$3,457
Lidocaine21$2,953
Memantine Hcl116$2,896
Gabapentin145$2,602
Morphine Sulfate59$1,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$212$6,21311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional pain management providers in Illinoison file to place this against a meaningful peer group, so we don't.

Other interventional pain management in Burr Ridge

Where these figures come from

Is this you, or does something look wrong? →